573675-55-5

Basic information

• Product Name: 7-BROMO-4-CHLOROQUINAZOLINE
• Synonyms: 7-BROMO-4-CHLOROQUINAZOLINE;7-BroMo-4-chloroquinazoli...
• CAS NO: 573675-55-5
• Molecular Formula: C₈H₄BrClN₂
• Molecular Weight: 243.48776
• Product Categories: Halides;CHIRAL CHEMICALS;Fused Ring Systems
• Mol File: 573675-55-5.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 339.695 °C at 760 mmHg
• Flash Point: 159.242 °C
• Appearance: /
• Density: 1.763 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.691
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 0.09±0.30(Predicted)
• CAS DataBase Reference: 7-BROMO-4-CHLOROQUINAZOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-BROMO-4-CHLOROQUINAZOLINE(573675-55-5)
• EPA Substance Registry System: 7-BROMO-4-CHLOROQUINAZOLINE(573675-55-5)

Safety Data

• Hazard Codes: T
• Statements: 41-25
• Safety Statements: 26-39-45
• RIDADR: UN2811
• Hazardous Substances Data: 573675-55-5(Hazardous Substances Data)

Usage

General Description

7-Bromo-4-chloroquinazoline is a chemical compound with the molecular formula C8H5BrClN2. It is a heterocyclic building block used in the synthesis of various pharmaceuticals and agrochemicals. 7-Bromo-4-chloroquinazoline is used as an intermediate in the production of pharmaceuticals, such as anticancer agents and anti-inflammatory drugs. It is also used in the production of agrochemicals, such as herbicides and insecticides. 7-Bromo-4-chloroquinazoline is a versatile compound with a wide range of applications in the pharmaceutical and agrochemical industries.

InChI:InChI=1/C8H4BrClN2/c9-5-1-2-6-7(3-5)11-4-12-8(6)10/h1-4H

Upstream product

• 135484-83-2 2-amino-4-bromo-benzoic acid methyl ester 
• 20776-50-5 2-amino-4-bromobenzoic acid 
• 194851-16-6 7-bromoquinazolin-4(3H)-one 
• 194851-16-6 7-bromo-4-hydroxyquinazoline 

Downstream Products

• 1334602-74-2 4-(4-chloroquinazolin-7-yl)morpholine 
• 1334602-75-3 7-bromo-4-((4-methoxybenzyl)oxy)quinazoline 
• 1186390-25-9 sodium methyl 4-(4-(5-(2-(3-fluorophenylamino)-2-oxoethyl)-1H-pyrazol-3-ylamino)quinazolin-7-yl)benzoate 
• 1186390-31-7 2-(4-(4-(4-(5-(2-(3-fluorophenylamino)-2-oxoethyl)-1H-pyrazol-3-ylamino)quinazolin-7-yl)benzoyl)piperazin-1-yl)ethyl dihydrogen phosphate 
• 1186390-17-9 C₃₈H₄₅FN₈O₃Si 
• 1186390-26-0 2-(3-(7-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinazolin-4-ylamino)-1H-pyrazol-5-yl)-N-(3-fluorophenyl)acetamide 
• 1186390-09-9 N-(3-fluorophenyl)-2-(3-(7-(4-(4-(2-hydroxyethyl)piperazine-1-carbonyl)phenyl)quinazolin-4-ylamino)-1H-pyrazol-5-yl)acetamide 
• 1186390-07-7 (S)-N-(3-fluorophenyl)-2-(3-(7-(4-(3-fluoropyrrolidin-1-ylsulfonyl)phenyl)quinazolin-4-ylamino)-1H-pyrazol-5-yl)acetamide 
• 1186390-24-8 methyl 4-(4-(5-(2-(3-fluorophenylamino)-2-oxoethyl)-1H-pyrazol-3-ylamino)quinazolin-7-yl)benzoate 
• 1186390-14-6 2-(3-(7-bromoquinazolin-4-ylamino)-1H-pyrazol-5-yl)-N-(3-fluorophenyl)acetamide 
• 1186390-23-7 N-(3-fluorophenyl)-2-(3-(quinazolin-4-ylamino)-1H-pyrazol-5-yl)acetamide 

Relevant articles and documents

Discovery of BPR1R024, an Orally Active and Selective CSF1R Inhibitor that Exhibits Antitumor and Immunomodulatory Activity in a Murine Colon Tumor Model

Colony-stimulating factor-1 receptor (CSF1R) is implicated in tumor-associated macrophage (TAM) repolarization and has emerged as a promising target for cancer immunotherapy. Herein, we describe the discovery of orally active and selective CSF1R inhibitors by property-driven optimization of BPR1K871 (9), our clinical multitargeting kinase inhibitor. Molecular docking revealed an additional nonclassical hydrogen-bonding (NCHB) interaction between the unique 7-aminoquinazoline scaffold and the CSF1R hinge region, contributing to CSF1R potency enhancement. Structural studies of CSF1R and Aurora kinase B (AURB) demonstrated the differences in their back pockets, which inspired the use of a chain extension strategy to diminish the AURA/B activities. A lead compound BPR1R024 (12) exhibited potent CSF1R activity (IC50 = 0.53 nM) and specifically inhibited protumor M2-like macrophage survival with a minimal effect on antitumor M1-like macrophage growth. In vivo, oral administration of 12 mesylate delayed the MC38 murine colon tumor growth and reversed the immunosuppressive tumor microenvironment with the increased M1/M2 ratio.

DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST

The present application belongs to the field of medicine. In particular, the present application relates to a diarylthiohydantoin compound as an androgen receptor antagonist or a pharmaceutically acceptable salt thereof, a preparation method of the same, a pharmaceutical composition comprising the compound, and a use thereof in treating a cell proliferative disease mediated by androgen. The compound of the present application has good antagonistic effect on androgen receptor and exhibits excellent antitumor effect.

A Scaffold-Hopping Strategy toward the Identification of Inhibitors of Cyclin G Associated Kinase

We recently reported the discovery of isothiazolo[4,3-b]pyridine-based inhibitors of cyclin G associated kinase (GAK) displaying low nanomolar binding affinity for GAK and demonstrating broad-spectrum antiviral activity. To come up with novel core structures that act as GAK inhibitors, a scaffold-hopping approach was applied starting from two different isothiazolo[4,3-b]pyridines. In total, 13 novel 5,6- and 6,6-fused bicyclic heteroaromatic scaffolds were synthesized. Four of them displayed GAK affinity with Kd values in the low micromolar range that can serve as chemical starting points for the discovery of GAK inhibitors based on a different scaffold.